Skip to main
SVRA

Savara (SVRA) Stock Forecast & Price Target

Savara (SVRA) Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 29%
Buy 57%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Savara Inc. is advancing its molgramostim nebulizer solution, currently in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), which has shown improved health-related quality of life and exercise capacity across various patient subgroups. The anticipated adoption of Molbreevi by pulmonologists exceeds current off-label GM-CSF usage, indicating a significant potential for blockbuster sales, and the estimated patient population has increased, thereby enhancing projected worldwide peak sales from approximately $1.2 billion to $1.6 billion. Furthermore, the company's strengthened probability of success for the Biologics License Application (BLA) approval, alongside a favorable safety profile and reduced regulatory uncertainty, positions Savara favorably for early market acceptance and robust financial performance.

Bears say

Savara Inc. faces significant risks that contribute to a negative outlook on its stock, primarily centered around the potential failure to secure regulatory approval for its molgramostim nebulizer solution, which could diminish market opportunities due to competition and pricing concerns. The company is projected to continue incurring net losses until commercialization and possibly through the early stages of product launch, exacerbated by a recent need to resubmit its Biologics License Application (BLA) after an initial rejection, raising uncertainties regarding the integrity of its manufacturing controls. Additionally, the limited market size for autoimmune pulmonary alveolar proteinosis (aPAP), with only an estimated 3,600 confirmed patients, alongside the high pricing of comparable treatments and barriers to insurance coverage, further complicates Savara's revenue potential and overall valuation.

Savara (SVRA) has been analyzed by 7 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 57% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Savara and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Savara (SVRA) Forecast

Analysts have given Savara (SVRA) a Buy based on their latest research and market trends.

According to 7 analysts, Savara (SVRA) has a Buy consensus rating as of Jan 9, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.86, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.86, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Savara (SVRA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.